291 related articles for article (PubMed ID: 25483948)
61. Cardiac Involvement in Fabry Disease: JACC Review Topic of the Week.
Pieroni M; Moon JC; Arbustini E; Barriales-Villa R; Camporeale A; Vujkovac AC; Elliott PM; Hagege A; Kuusisto J; Linhart A; Nordbeck P; Olivotto I; Pietilä-Effati P; Namdar M
J Am Coll Cardiol; 2021 Feb; 77(7):922-936. PubMed ID: 33602475
[TBL] [Abstract][Full Text] [Related]
62. Fabry disease: cardiac manifestations and therapeutic options.
Pierre-Louis B; Kumar A; Frishman WH
Cardiol Rev; 2009; 17(1):31-5. PubMed ID: 19092368
[TBL] [Abstract][Full Text] [Related]
63. Arrhythmias in Fabry cardiomyopathy.
Acharya D; Doppalapudi H; Tallaj JA
Card Electrophysiol Clin; 2015 Jun; 7(2):283-91. PubMed ID: 26002392
[TBL] [Abstract][Full Text] [Related]
64. Multimodality imaging for pre-clinical assessment of Fabry's cardiomyopathy.
Madonna R; Cevik C; Cocco N
Eur Heart J Cardiovasc Imaging; 2014 Oct; 15(10):1094-100. PubMed ID: 24904036
[TBL] [Abstract][Full Text] [Related]
65. Electrophysiological findings in Fabry cardiomyopathy: mapping the maze of risk stratification.
Li J; Warth A; Schnabel P; Schweizer PA; Buss SJ; Steen H; Becker R; Katus HA; Thomas D
Acta Cardiol; 2012 Aug; 67(4):481-5. PubMed ID: 22998007
[TBL] [Abstract][Full Text] [Related]
66. Fabry disease: diagnosis and treatment.
Breunig F; Weidemann F; Beer M; Eggert A; Krane V; Spindler M; Sandstede J; Strotmann J; Wanner C
Kidney Int Suppl; 2003 May; (84):S181-5. PubMed ID: 12694340
[TBL] [Abstract][Full Text] [Related]
67. Diagnosis and Management of Cardiovascular Involvement in Fabry Disease.
Rubino M; Monda E; Lioncino M; Caiazza M; Palmiero G; Dongiglio F; Fusco A; Cirillo A; Cesaro A; Capodicasa L; Mazzella M; Chiosi F; Orabona P; Bossone E; Calabrò P; Pisani A; Germain DP; Biagini E; Pieroni M; Limongelli G
Heart Fail Clin; 2022 Jan; 18(1):39-49. PubMed ID: 34776082
[TBL] [Abstract][Full Text] [Related]
68. T₁ mapping with cardiovascular MRI is highly sensitive for Fabry disease independent of hypertrophy and sex.
Thompson RB; Chow K; Khan A; Chan A; Shanks M; Paterson I; Oudit GY
Circ Cardiovasc Imaging; 2013 Sep; 6(5):637-45. PubMed ID: 23922004
[TBL] [Abstract][Full Text] [Related]
69. Segment-by-segment assessment of left ventricular myocardial affection in Anderson-Fabry disease by non-enhanced T1-mapping.
Walter TC; Knobloch G; Canaan-Kuehl S; Greiser A; Sandek A; Blaschke D; Denecke T; Hamm B; Makowski MR
Acta Radiol; 2017 Aug; 58(8):914-921. PubMed ID: 27799574
[TBL] [Abstract][Full Text] [Related]
70. [Fabry disease: diagnostic due of substitutive enzyme-therapy].
Barbey F; Widmer U; Burnier M; Lidove O
Rev Med Suisse Romande; 2002 Sep; 122(9):449-53. PubMed ID: 12422475
[TBL] [Abstract][Full Text] [Related]
71. α-Galactosidase A Genotype N215S Induces a Specific Cardiac Variant of Fabry Disease.
Oder D; Liu D; Hu K; Üçeyler N; Salinger T; Müntze J; Lorenz K; Kandolf R; Gröne HJ; Sommer C; Ertl G; Wanner C; Nordbeck P
Circ Cardiovasc Genet; 2017 Oct; 10(5):. PubMed ID: 29018006
[TBL] [Abstract][Full Text] [Related]
72. Long-Term Effects of Enzyme Replacement Therapy for Anderson-Fabry Disease.
Tsujiuchi M; Ebato M; Maezawa H; Mizukami T; Nogi A; Ikeda N; Iso Y; Suzuki H
Int Heart J; 2019 Jan; 60(1):208-214. PubMed ID: 30464119
[TBL] [Abstract][Full Text] [Related]
73. [Fabry disease in adulthood: clinical aspects and therapeutic progress].
Lidove O; Joly D; Barbey F; Blétry O; Grünfeld JP
Rev Med Interne; 2001 Dec; 22 Suppl 3():384s-392s. PubMed ID: 11794883
[TBL] [Abstract][Full Text] [Related]
74. Fabry disease - Vascular manifestations.
Karetova D; Bultas J; Dostalova G; Palecek T; Kovarnik T; Golan L; Linhart A
Vasa; 2010 May; 39(2):123-31. PubMed ID: 20464667
[TBL] [Abstract][Full Text] [Related]
75. High-Sensitivity Troponin: A Clinical Blood Biomarker for Staging Cardiomyopathy in Fabry Disease.
Seydelmann N; Liu D; Krämer J; Drechsler C; Hu K; Nordbeck P; Schneider A; Störk S; Bijnens B; Ertl G; Wanner C; Weidemann F
J Am Heart Assoc; 2016 May; 5(6):. PubMed ID: 27247331
[TBL] [Abstract][Full Text] [Related]
76. Biomarkers for Diagnosing and Staging of Fabry Disease.
Kramer J; Weidemann F
Curr Med Chem; 2018; 25(13):1530-1537. PubMed ID: 28618999
[TBL] [Abstract][Full Text] [Related]
77. [Diagnosis of Fabry disease: usefulness of the clinical investigation].
Demontis R
Rev Med Interne; 2010 Dec; 31 Suppl 2():S229-32. PubMed ID: 21211670
[TBL] [Abstract][Full Text] [Related]
78. Fabry Cardiomyopathy: Current Practice and Future Directions.
Yim J; Yau O; Yeung DF; Tsang TSM
Cells; 2021 Jun; 10(6):. PubMed ID: 34204530
[TBL] [Abstract][Full Text] [Related]
79. Fabry disease--a diagnostic and therapeutic problem.
Strujić BJ; Jeren T
Ren Fail; 2005; 27(6):783-6. PubMed ID: 16350834
[TBL] [Abstract][Full Text] [Related]
80. Cross-sectional baseline analysis of electrocardiography in a large cohort of patients with untreated Fabry disease.
Niemann M; Hartmann T; Namdar M; Breunig F; Beer M; Machann W; Herrmann S; Ertl G; Wanner C; Weidemann F
J Inherit Metab Dis; 2013 Sep; 36(5):873-9. PubMed ID: 23053470
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
